STAT+: Detailed data confirm Moderna and Merck cancer vaccine met key endpoints in melanoma trial

Moderna and Merck's personalized mRNA cancer vaccine intismeran autogene met key endpoints in a melanoma clinical trial, reducing the risk of disease recurrence by 42% compared to standard treatment. The results showed patients lived significantly longer without their cancer returning. The therapy targets unique mutations in patients' tumors called neoantigens.